<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /><meta http-equiv="Content-Language" content="en" /><title>Verbatim report of proceedings - Health technology assessment (debate) - Monday, 13 December 2021</title><meta name="title" content="Verbatim report of proceedings - Health technology assessment (debate) - Monday, 13 December 2021" /><meta name="language" content="en" /><meta name="robots" content="index, follow, noodp, noydir, notranslate" /><meta name="copyright" content="© European Union, 2021 - Source: European Parliament" /><meta name="available" content="13-12-2021" /><meta name="sipade-leg" content="9" /><meta name="sipade-type" content="CRE" /><meta property="og:title" content="Verbatim report of proceedings - Health technology assessment (debate) - Monday, 13 December 2021" /><meta property="og:image" content="https://www.europarl.europa.eu/website/common/img/icon/sharelogo_facebook.jpg" /><link rel="canonical" href="https://www.europarl.europa.eu/doceo/document/CRE-9-2021-12-13-ITM-019_EN.html" /><link href="/doceo/data/css/style_common.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_common_print.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_sipade.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_activities.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/common_sides.css" type="text/css" rel="stylesheet" /><link href="/doceo/data/css/style_sipade_oj_sched.css" type="text/css" rel="stylesheet" />
<script src="/doceo/data/js/overlib.js" type="text/javascript"> </script>
<script src="/doceo/data/js/swap_images.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade.js" type="text/javascript"> </script>
<script src="/doceo/data/js/jquery-1.4.4.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade-OJ-SYN.js" type="text/javascript"> </script><!--ATI analytics script--><script type="text/javascript" data-tracker-name="ATInternet" defer data-value="/website/webanalytics/ati-doceo.js" src="//www.europarl.europa.eu/website/privacy-policy/privacy-policy.js" ></script></head><body bgcolor="#FFFFFF"><div id="overDiv" style="position:absolute; visibility:hidden; z-index:1000;"> </div><a name="top"></a><table cellpadding="0" cellspacing="0" border="0" width="100%"><tr><td><div id="header_sides" class="new">
<a href="/portal/en"><img alt="Go back to the Europarl portal" title="Go back to the Europarl portal" src="/doceo/data/img/EP_logo_neg_EN.png" /></a><h3 class="ep_hidden">Choisissez la langue de votre document :</h3><ul class="language_select">
            <li><a title="bg - български" class="bg on" href="/doceo/document/CRE-9-2021-12-13-ITM-019_BG.html">bg - български</a></li>
            <li><a title="es - español" class="es on" href="/doceo/document/CRE-9-2021-12-13-ITM-019_ES.html">es - español</a></li>
            <li><a title="cs - čeština" class="cs on" href="/doceo/document/CRE-9-2021-12-13-ITM-019_CS.html">cs - čeština</a></li>
            <li><a title="da - dansk" class="da on" href="/doceo/document/CRE-9-2021-12-13-ITM-019_DA.html">da - dansk</a></li>
            <li><a title="de - Deutsch" class="de on" href="/doceo/document/CRE-9-2021-12-13-ITM-019_DE.html">de - Deutsch</a></li>
            <li><a title="et - eesti keel" class="et on" href="/doceo/document/CRE-9-2021-12-13-ITM-019_ET.html">et - eesti keel</a></li>
            <li><a title="el - ελληνικά" class="el on" href="/doceo/document/CRE-9-2021-12-13-ITM-019_EL.html">el - ελληνικά</a></li>
            <li class="en selected" title="en - English">en - English<span> (Selected)</span></li>
            <li><a title="fr - français" class="fr on" href="/doceo/document/CRE-9-2021-12-13-ITM-019_FR.html">fr - français</a></li>
            <li class="ga" title="ga - Gaeilge">ga - Gaeilge</li>
            <li><a title="hr - hrvatski" class="hr on" href="/doceo/document/CRE-9-2021-12-13-ITM-019_HR.html">hr - hrvatski</a></li>
            <li><a title="it - italiano" class="it on" href="/doceo/document/CRE-9-2021-12-13-ITM-019_IT.html">it - italiano</a></li>
            <li><a title="lv - latviešu valoda" class="lv on" href="/doceo/document/CRE-9-2021-12-13-ITM-019_LV.html">lv - latviešu valoda</a></li>
            <li><a title="lt - lietuvių kalba" class="lt on" href="/doceo/document/CRE-9-2021-12-13-ITM-019_LT.html">lt - lietuvių kalba</a></li>
            <li><a title="hu - magyar" class="hu on" href="/doceo/document/CRE-9-2021-12-13-ITM-019_HU.html">hu - magyar</a></li>
            <li><a title="mt - Malti" class="mt on" href="/doceo/document/CRE-9-2021-12-13-ITM-019_MT.html">mt - Malti</a></li>
            <li><a title="nl - Nederlands" class="nl on" href="/doceo/document/CRE-9-2021-12-13-ITM-019_NL.html">nl - Nederlands</a></li>
            <li><a title="pl - polski" class="pl on" href="/doceo/document/CRE-9-2021-12-13-ITM-019_PL.html">pl - polski</a></li>
            <li><a title="pt - português" class="pt on" href="/doceo/document/CRE-9-2021-12-13-ITM-019_PT.html">pt - português</a></li>
            <li><a title="ro - română" class="ro on" href="/doceo/document/CRE-9-2021-12-13-ITM-019_RO.html">ro - română</a></li>
            <li><a title="sk - slovenčina" class="sk on" href="/doceo/document/CRE-9-2021-12-13-ITM-019_SK.html">sk - slovenčina</a></li>
            <li><a title="sl - slovenščina" class="sl on" href="/doceo/document/CRE-9-2021-12-13-ITM-019_SL.html">sl - slovenščina</a></li>
            <li><a title="fi - suomi" class="fi on" href="/doceo/document/CRE-9-2021-12-13-ITM-019_FI.html">fi - suomi</a></li>
            <li><a title="sv - svenska" class="sv on" href="/doceo/document/CRE-9-2021-12-13-ITM-019_SV.html">sv - svenska</a></li>
        </ul></div></td></tr><tr><td style="padding:10px;"><table width="100%" border="0" cellspacing="0" cellpadding="0"><tr><td><table border="0" align="left" cellpadding="0" cellspacing="0"><tr><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-9-2021-12-13-TOC_EN.html"><img src="/doceo/data/img/navi_index.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-9-2021-12-13-TOC_EN.html" title="Index">Index</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-9-2021-12-13-ITM-018_EN.html"><img src="/doceo/data/img/navi_previous.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-9-2021-12-13-ITM-018_EN.html" title="Previous">Previous</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td valign="middle"> <a href="/doceo/document/CRE-9-2021-12-13-ITM-020_EN.html" title="Next">Next</a> </td><td><a href="/doceo/document/CRE-9-2021-12-13-ITM-020_EN.html"><img src="/doceo/data/img/navi_next.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-9-2021-12-13_EN.html"><img src="/doceo/data/img/navi_moredetails.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-9-2021-12-13_EN.html" title="Full text">Full text</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td></tr><tr><td><img src="/doceo/data/img/spacer.gif" width="10" height="15" alt="" /></td></tr></table></td></tr></table><table width="100%" border="0" cellpadding="5" cellspacing="0" class="doc_box_header">
<tr>
<td align="left" valign="top" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="title_TA">Verbatim report of proceedings</td><td valign="top" align="right" style="background-image:url(/doceo/data/img/gradient_blue.gif)">
<table border="0" cellspacing="0" cellpadding="0"><tr>
<td><a href="/doceo/document/CRE-9-2021-12-13-ITM-019_EN.xml"><img src="/doceo/data/img/formats/icn_xml.gif" border="0" align="bottom" alt="XML" title="XML" /></a><span class="doc_size"> 43k</span></td></tr>
</table></td>
</tr>
<tr>
<td class="doc_title" align="left" valign="top" bgcolor="#F5F5F5">Monday, 13 December 2021 - Strasbourg</td>
<td class="doc_title" align="right" valign="top" bgcolor="#F5F5F5">Revised edition</td></tr></table><br />
<table width="100%" border="0" cellpadding="0" cellspacing="0" class="doc_box_header" style="padding-bottom:5px"><tr valign="top"><td>
<table width="100%" border="0" cellpadding="5" cellspacing="0"><tr valign="top" style="padding-bottom:0px;padding-left:5px;padding-right:5px;padding-top:5px"><td align="left" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="doc_title"><img src="/doceo/data/img/arrow_title_doc.gif" width="8" height="14" border="0" align="absmiddle" alt="" /> 19. Health technology assessment (debate)</td><td style="background-image:url(/doceo/data/img/gradient_blue.gif)" width="10"><table cellSpacing="0" cellPadding="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20211213-19:50:25&amp;playerEndTime=20211213-20:28:57" target="_blank"><img width="29" height="20" src="/doceo/data/img/vod_all_speakers_left.gif" border="0" /></a></td><td class="switch_button_pv_cre"><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20211213-19:50:25&amp;playerEndTime=20211213-20:28:57" target="_blank">Video of the speeches</a></td><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20211213-19:50:25&amp;playerEndTime=20211213-20:28:57" target="_blank"><img width="5" height="20" src="/doceo/data/img/switch_pv_cre_right.gif" border="0" /></a></td></tr></table></td><td style="background-image:url(/doceo/data/img/gradient_blue.gif)" width="10"><table align="right" cellpadding="0" cellspacing="0"><tr><td><a href="/doceo/document/PV-9-2021-12-13-ITM-019_EN.html" title="Minutes"><img src="/doceo/data/img/switch_pv_cre_left.gif" width="22" height="20" border="0" alt="" /></a></td><td class="switch_button_pv_cre"><a href="/doceo/document/PV-9-2021-12-13-ITM-019_EN.html" title="Minutes">PV</a></td><td><a href="/doceo/document/PV-9-2021-12-13-ITM-019_EN.html" title="Minutes"><img src="/doceo/data/img/switch_pv_cre_right.gif" width="5" height="20" border="0" alt="" /></a></td></tr></table></td></tr></table>
<a name="1-116-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/2054.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20211213-19:50:25&amp;playerEndTime=20211213-19:51:23" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Puhemies. – </span></span>  Esityslistalla on seuraavana keskustelu ympäristön, kansanterveyden ja elintarvikkeiden turvallisuuden valiokunnan suosituksesta toiseen käsittelyyn neuvoston ensimmäisen käsittelyn kannasta Euroopan parlamentin ja neuvoston asetuksen antamiseksi terveysteknologian arvioinnista ja direktiivin 2011/24/EU muuttamisesta (10531/3/2021 – C9—0422/2021 - <a href="https://oeil.secure.europarl.europa.eu/oeil/popups/ficheprocedure.do?lang=en&amp;reference=2018/0018(COD)">2018/0018(COD)</a>) (Esittelijä: Tiemo Wölken) (<a href="/doceo/document/A-9-2021-0334_EN.html">A9-0334/2021</a>).</p>
<p class="contents">Haluan ensin kuitenkin muistuttaa, että tällä istuntojaksolla keskusteluissa ei anneta pyynnöstä myönnettäviä puheenvuoroja eikä sinisen kortin kysymyksiä hyväksytä. </p>
<p class="contents">Huomautan vielä, että viimeaikaisten istuntojaksojen tapaan puheenvuoroja on mahdollista käyttää etäyhteydellä jäsenvaltioiden yhteystoimistoista.</p>
<p class="contents">Muistutan myös, että istuntosalissa puheenvuorot käytetään edelleen istuntosalin keskellä olevalta puhujakorokkeelta. Kehotankin teitä seuraamaan puhujalistaa ja siirtymään puhujakorokkeen lähelle, kun puheaikanne on alkamassa.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-117-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/185619.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20211213-19:51:23&amp;playerEndTime=20211213-19:53:54" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Tiemo Wölken, </span></span>  <span class="italic">Berichterstatter</span><span class="bold">.</span> – Frau Präsidentin Hautala, sehr geehrte Frau Kommissarin Kyriakides, liebe Kolleginnen und Kollegen! Es ist zwar noch nicht ganz Weihnachten, aber wir können heute schon, denke ich, ein kleines Geschenk auspacken.</p>
<p class="contents">Nach fast vier Jahren Verhandlungen, nach acht EU-Ratspräsidentschaften, sechzehn technischen und drei politischen Trilogen ist es heute so weit: Der finale Abschluss der Verordnung über die Bewertung von Gesundheitstechnologien – kurz: HTA – steht an. Ich möchte als Berichterstatter zunächst hervorheben, dass das ein Teamerfolg war. Deswegen möchte ich mich zunächst bei den Schattenberichterstatterinnen und Schattenberichterstattern bedanken, aber eben auch bei der Kommission, sehr geehrte Frau Kommissarin, für die konstruktive Zusammenarbeit.</p>
<p class="contents">Die Pandemie führt uns noch immer vor Augen, dass wir als Europäerinnen und Europäer gemeinsam stärker sind. Es ist wichtig, unser Fachwissen, unsere Ressourcen miteinander zu teilen und zu bündeln. Diese Pandemie zeigt, wie notwendig eine starke, integrative Europäische Gesundheitsunion ist. </p>
<p class="contents">Es freut mich daher, dass wir mit der heutigen Verabschiedung der HTA-Verordnung nicht nur die EU-Zusammenarbeit zwischen den Mitgliedstaaten stärken, sondern eben auch einen weiteren Schritt in Richtung Gesundheitsunion gehen. Mit den neuen Regeln zur Bewertung von Gesundheitstechnologien unterstützen wir die Entscheidungsfindung im Gesundheitswesen, ob ein neues Arzneimittel, ein Medizinprodukt oder ein neues Diagnoseinstrument verwendet werden kann. Wir schaffen damit einen Mehrwert für die Patientinnen und Patienten. </p>
<p class="contents">In einem ersten Schritt werden nicht nur Medikamente zur Behandlung von Krebs getestet, sondern auch Arzneimittel für neuartige … </p>
<p class="contents">Wir können von Anfang an dafür sorgen, dass innovative Arzneimittel europäisch bewertet werden und eine Fragmentierung des Marktes vermieden wird.</p>
<p class="contents">Sorry, I am not feeling so well, so I will stop here. I am going to sit down and I will continue at the end but, dear Commissioner, thanks once again for being here and thank you very much for the good cooperation. I look forward to the debate.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-119-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/doceo/data/img/photo_generic.gif" align="right" width="50" height="63" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20211213-19:54:35&amp;playerEndTime=20211213-19:59:14" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Stella Kyriakides,</span></span>   <span class="italic">Member of the Commission</span><span class="bold">.</span> – Madam President, I am delighted to join you today to celebrate the long—awaited adoption of the Regulation on Health Technology Assessment (HTA). In 2018, we presented our proposal for a regulation on health technology assessment in this House. Three years and many meetings later – Mr Wölken listed the number of meetings – I am very pleased to be here to see the conclusion of this challenge, a very important process. </p>
<p class="contents">I would also like to thank once again the rapporteur, Tiemo Wölken, and the European Parliament for their very constructive approach and commitment to this file throughout the negotiations for the benefit of EU patients. This regulation represents the very first output of the pharmaceutical strategy for Europe and is integral in ensuring a stronger European health union. It builds on many years of hard work by experts across the EU and the experience gathered during the three EU net HTA joint actions, facilitating cooperation between Member States. It provides a comprehensive and sustainable legal framework to make a much—needed step forward and it will deliver concrete benefits to our citizens, our Member States and our healthcare systems. </p>
<p class="contents">The HTA Regulation will enable high—quality joint clinical assessments of innovative medicines and some medical devices at EU level. It will secure inclusiveness and transparency in the health technology assessment process, and it will increase predictability for Member States’ authorities and for industry. It will help Member States to take more timely and evidence-based decisions on patient access to innovative technologies within healthcare systems.</p>
<p class="contents">Let me give you an example. The joint work will start by assessing cancer medicines and advanced therapies like gene therapies. These are the type of products which are scientifically complex to assess and, at the same time, so very challenging to ensure access to across the EU. Pooling resources and expertise will be key to support all Member States in their national decisions and negotiations.</p>
<p class="contents">While the text of the regulation changed throughout the negotiations, the final compromise maintains the key elements of the Commission proposal, which the European Parliament shared and supported. The joint work will target the scientific clinical aspects of health technology assessment. The national health technology assessment bodies will drive the joint work, and the joint work will be of the highest quality, provided in a timely manner and produced following inclusive and transparent procedures. </p>
<p class="contents">I want to stress the point on inclusiveness and transparency, which I know was especially important to this Parliament. You were determined to ensure that the involvement of external experts and stakeholder organisations was well reflected in the final compromise. So I am truly very pleased with the outcome, as the general involvement of stakeholders in the HTA process is essential to ensure the quality of work.</p>
<p class="contents">I want to close by highlighting two important points. First, this is about patients and improving access to innovative technology. And second, with this regulation we’re building a new type of cooperation in health among Member States. More than ever, the current pandemic has underlined the need for enhanced cooperation between Member States, and this regulation reflects and responds to that need. It is another important step towards a stronger European health union. With this regulation, we are giving health experts, producers, and most importantly of all, patients, a new framework that will help us to address unmet medical needs and facilitate access to innovative medicines and medical devices. </p>
<p class="contents">I want once again to thank the rapporteur, the shadow rapporteurs and every Member of the Parliament for supporting this, and I look forward to continuing working together to ensure the new rules are successfully implemented in a timely manner. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-120-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/197536.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20211213-19:59:28&amp;playerEndTime=20211213-20:01:50" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Nathalie Colin-Oesterlé, </span></span>  <span class="italic">au nom du groupe PPE</span><span class="bold">.</span> – Madame la Présidente, Madame la Commissaire, tout d’abord, je voulais réitérer toutes mes félicitations à notre collègue rapporteur et lui souhaiter un bon rétablissement.</p>
<p class="contents">Aujourd’hui, en Europe, ce ne sont pas moins de 50 agences nationales qui évaluent la plus-value d’un nouveau médicament qui est mis sur le marché. Cette approche fragmentée a un impact négatif sur la recherche et le développement, sur la rapidité des processus d’approbation et sur l’égalité d’accès aux soins pour les Européens. Le règlement que nous adopterons cette semaine est un premier pas vers une harmonisation de ces systèmes d’évaluation.</p>
<p class="contents">Alors, certes, nous aurions aimé aller plus loin, l’objectif initial étant de n’avoir plus qu’une seule évaluation européenne. Si les États membres ont souhaité conserver leurs agences nationales, ce règlement permettra qu’à terme, les médicaments innovants soient accessibles partout en Europe, au même moment et pour tous les citoyens. Il sera par exemple utile aux deux millions et demi d’Européens qui sont frappés chaque année par le cancer. Ces malades n’ont parfois pas accès à de nouveaux traitements qui sont disponibles dans l’État membre voisin, mais indisponibles ou non autorisés dans le leur. Il le sera également aux 7 à 8 millions de Français qui souffrent de migraines sévères et qui voient certains médicaments de nouvelle génération autorisés et remboursés en Allemagne ou en Italie, mais pas en France.</p>
<p class="contents">Grâce au Parlement européen, les anticancéreux sont les premières technologies qui pourront bénéficier de ce règlement. Puis viendra le tour des médicaments orphelins et tous les traitements à l’horizon 2030. Permettre l’accès à l’innovation médicale partout en Europe est une priorité et cette priorité s’intègre dans un enjeu beaucoup plus global, celui de l’égalité d’accès aux soins pour tous les Européens. Pendant la crise sanitaire, les achats groupés de vaccins ont répondu à cet enjeu et rappelé à chacun d’entre nous son importance. Un accès égal aux soins pour tous les Européens, c’est pouvoir obtenir son traitement partout en Europe, c’est pouvoir savoir où il est disponible et comment l’obtenir, c’est pouvoir se faire soigner n’importe où en Europe par des professionnels qualifiés.</p>
<p class="contents">C’est cet objectif que vise ce règlement et c’est parce qu’il répond aux besoins les plus élémentaires des patients qu’il est une avancée majeure pour l’Europe de la santé.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-121-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124991.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20211213-20:02:07&amp;playerEndTime=20211213-20:03:48" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Jytte Guteland, </span></span>  <span class="italic">för S&amp;D-gruppen</span><span class="bold">.</span> – Fru talman! Utvecklingen av nya mediciner och medicinska teknologier går allt snabbare. Det märks tydligt i hur snabbt vi fick fram effektiva och säkra vaccin med ny teknik. Den nya tekniken är ibland mycket kostsam. Med fler möjligheter kommer oundvikligen också fler prioriteringar. När vi prioriterar, då kan vi antingen göra det godtyckligt eller så kan vi använda beprövade och forskningsbaserade verktyg.</p>
<p class="contents">I dag tar vi tydligt ställning för att använda just de verktygen för att få ut och få fram så många bra mediciner som möjligt i hela EU. Vi stoppar det dubbelarbete som finns i olika EU-länder, där man utvärderar medicinska tekniker. Vi tar chansen att lära av varandra och stötta de mindre länder som också har mindre resurser. Det kan handla om verktyg för att tidigare ställa en diagnos för en sällsynt sjukdom eller nya verktyg för att kartlägga smittspridning, eller för att få fram den där nya effektiva behandlingen för cancer. </p>
<p class="contents">Efter tre års förhandlade från medlemsstaternas sida har vi nu äntligen en överenskommelse. I tider av hälsokris har EU:s gemensamma svar nu nått ännu en framgång.</p>
<p class="contents">Jag vill tacka vår kollega Tiemo Wölken som har varit huvudförhandlare, och som har säkrat den socialdemokratiska gruppens prioriteringar – att få ett transparent system på plats som också är präglat av allmänintresset framför vinstintresset.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-122-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/197593.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20211213-20:03:59&amp;playerEndTime=20211213-20:06:11" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Véronique Trillet-Lenoir, </span></span>  <span class="italic">au nom du groupe Renew</span><span class="bold">.</span> – Madame la Présidente, Madame la Commissaire, chers collègues, il n’y a aucune raison pour que la valeur ajoutée d’un quelconque médicament soit différente entre deux États membres pour une situation médicale identique. Pourtant, après leur enregistrement par l’Agence européenne du médicament, les produits de santé font l’objet d’une évaluation menée concomitamment, mais sans convergence, dans les 27 pays de l’Union.</p>
<p class="contents">Ce manque de concertation génère des coûts inutiles pour les 27, un risque d’iniquité lié à des préoccupations économiques différentes, mais surtout, compte tenu de la lourdeur bureaucratique répétée 27 fois pour un même industriel de santé, un retard à la mise à disposition des innovations pour les patients.</p>
<p class="contents">Le nouveau règlement «Évaluation des technologies de santé» est enfin sorti de l’oubli grâce aux efforts de la Commission, de la présidence portugaise du Conseil et surtout de ce Parlement, et merci à Tiemo Wölken pour sa détermination. Ce règlement va permettre de démarrer enfin des évaluations communes centrées sur la science. Malheureusement pas avant 2024, et malheureusement pas pour toutes les innovations, mais c’est un premier pas très important pour l’Europe des médicaments. Car il n’y a pas non plus de raison pour que le prix d’un médicament soit différent d’un pays à l’autre. Et ce premier pas est celui du cercle vertueux par lequel l’Union européenne pourra non seulement évaluer, mais aussi négocier d’une seule voix et conjointement les produits de santé à leur juste prix, sur le modèle de ce que nous avons réussi pour les vaccins.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-123-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96743.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20211213-20:06:29&amp;playerEndTime=20211213-20:08:22" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Michèle Rivasi, </span></span>  <span class="italic">au nom du groupe Verts/ALE</span><span class="bold">.</span> – Madame la Présidente, enfin, nous voici arrivés au terme d’un bras de fer qui a duré près de cinq ans pour trouver des compromis satisfaisants pour l’évaluation des technologies de santé.</p>
<p class="contents">Jusqu’à présent, c’est vrai que cette évaluation était menée au niveau national, ce qui défavorisait les petits pays qui n’ont pas toujours les ressources nécessaires pour évaluer l’efficacité comparative des traitements et donc de fixer le remboursement des technologies de la santé.</p>
<p class="contents">Cette évaluation, effectivement, doit se faire au niveau européen, mais moi, je suis aussi favorable à ce que les autorités nationales y participent. Pourquoi? Je vais prendre l’exemple du remdésivir, l’antiviral du laboratoire Gilead, qui a été le premier traitement contre la COVID-19 à recevoir une autorisation européenne de mise sur le marché conditionnelle le 3 juillet 2020. Qu’en est-il de sa valeur ajoutée? Pour les autorités nationales françaises, le 17 septembre 2020, la Haute Autorité de santé disait: aucune valeur ajoutée, absence de démonstration de l’impact sur la charge virale de cet antiviral. Que décide la DG Santé de la Commission? Elle signe un contrat avec le laboratoire Gilead pour commander 500 000 doses, ce qui représente plus d’un milliard. Il n’y a pas de remise en cause, justement, de cette valeur ajoutée. L’OMS a déclaré que c’était un médicament toxique qui pouvait entraîner des effets nocifs.</p>
<p class="contents">Alors, j’espère que ce nouveau règlement permettra de ne pas prendre l’exemple de ce remdésivir et qu’on ait une véritable évaluation objective par rapport à ce que nous disent les laboratoires pharmaceutiques.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-124-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/128483.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20211213-20:08:31&amp;playerEndTime=20211213-20:09:41" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Markus Buchheit, </span></span>  <span class="italic">im Namen der ID-Fraktion</span><span class="bold">.</span> – Frau Präsidentin, meine sehr verehrten Damen und Herren, liebe Kollegen! Nach Meinung der deutschen Ärztekammer freut sich über den vorliegenden Vorschlag vor allem einer, nämlich die Industrie. Sie sagt, das Risiko externer Einflussnahme würde durch den Vorschlag gesteigert werden in Zukunft. Es geht natürlich um Lobbyarbeit, und diese Lobby, die hier gerade auch in Brüssel natürlich sehr, sehr stark aktiv ist, die freut sich darüber, was hier gerade passiert. Die freut sich über Zentralisierung. Sie muss erheblich weniger Geld in die Hand nehmen, um in Brüssel tätig zu werden. </p>
<p class="contents">Und ich glaube, dass Gesundheitspolitik, egal ob auf nationaler Ebene oder hier eben bei uns in Brüssel, vornehmlich von einer Sache abhängt, nämlich Vertrauen. Können wir einer Sache Vertrauen schenken? Können wir der Kommission in dieser Angelegenheit Vertrauen schenken, deren Präsidentin massenhaft Chats mit dem Pfizer-CEO ausgetauscht hat, die jetzt nunmehr alle verschwunden sind? </p>
<p class="contents">Können wir wirklich Ursula von der Leyen hier Vertrauen schenken, deren Ehemann medizinischer Direktor der Firma Orgenesis in den USA ist? Ich glaube, es geht um Vertrauen. Und ob hier wirklich Vertrauen geschenkt werden kann, das ist für mich fraglich.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-125-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/197530.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20211213-20:09:52&amp;playerEndTime=20211213-20:11:24" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Joanna Kopcińska, </span></span>  <span class="italic">w imieniu grupy ECR</span><span class="bold">.</span> – Pani Przewodnicząca! Panie pośle sprawozdawco! Podzielam pogląd, że należy wspierać ujednolicanie narzędzi, źródeł danych i metodykę HTA, jak również ograniczać zbędne powielanie prac. Opowiadam się za HTA, w którym wyniki raportu ze wspólnej oceny klinicznej są należycie uwzględnione, ale nie stanowią obowiązku. </p>
<p class="contents">Pozostałe inicjatywy odnośnie do HTA nazwałabym dzisiaj działaniami lepszymi. Niemniej jednak znane przysłowie mówi, że czasami lepsze jest wrogiem dobrego. Dodatkowe rozwiązania stanowić mogą potencjalne przeszkody oraz utrudnienia w kontekście organizacji systemów opieki zdrowotnej państw członkowskich, zwłaszcza odnośnie do decyzji o poziomie refundacji leków, ale również mogą doprowadzić do rozbieżności między krajowymi i unijnymi danymi. </p>
<p class="contents">Uważam, że kompromisem pomiędzy lepszymi a obecnymi dobrymi rozwiązaniami byłoby wypracowanie wspólnego stanowiska w kontekście oczekiwanego poziomu prac oraz ustalenie wspólnych standardów metod oceny. Przeprowadzenie oceny zaś należy pozostawić na poziomie narodowym. Niemniej doceniam pracę pana posła sprawozdawcy, bardzo za nią dziękuję i mimo że czasami się różnimy, naprawdę szanuję pańskie zaangażowanie.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-126-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/1927.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20211213-20:11:39&amp;playerEndTime=20211213-20:14:00" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Peter Liese (PPE).</span></span>   – Frau Präsidentin, liebe Kolleginnen und Kollegen! Ich möchte besonders die Bedeutung der vorliegenden Gesetzgebung für die Krebspatienten in Europa hervorheben.</p>
<p class="contents">Sie werden als erstes davon profitieren, dass wir bei der Nutzenbewertung effizienter werden. Als die EVP 2018 zum ersten Mal systematisch gefragt hat, wie wir Patienten, die an Krebs leiden, besser helfen können, war eine unserer Forderungen: HTA muss angenommen werden. Ich freue mich, dass wir das jetzt endlich geschafft haben.</p>
<p class="contents">Die Institutionen, die für die Nutzenbewertung zuständig sind, müssen in Zukunft mit der Europäischen Arzneimittelagentur zusammenarbeiten. Das kann gerade bei Krebspatienten dazu führen, dass wir wirkliche Innovationen bekommen und wenig Scheininnovation. In der Frauenpolitik ist <span class="italic">MeToo</span> notwendig und dringend. In der Arzneimittelpolitik ist <span class="italic">MeToo</span> Verschwendung von Ressourcen. Das bedeutet nämlich: Eine Firma bringt nur ein Medikament auf den Markt, um ein Stück vom Kuchen abzubekommen, ohne dass es eine wirkliche Innovation für die Patientinnen und Patienten darstellt. Und wenn man rechtzeitig signalisiert bekommt in der Kooperation EMA und HTA-Institutionen: Das ist keine wirkliche Innovation, da kriegt man vielleicht eine Zulassung, aber niemals eine Erstattung – dann konzentriert man sich hoffentlich auf wirkliche Durchbrüche wie zum Beispiel die mRNA-Technologie gegen Krebs. </p>
<p class="contents">Ich danke allen, die mitgeholfen haben, zu diesem Ergebnis zu kommen: Tiemo Wölken, Nathalie Colin-Oesterlé für die EVP, Stella als Kommissarin. </p>
<p class="contents">Ich glaube, wir werden mit diesem Vorschlag Ressourcen schonen und Doppelarbeit vermeiden. Die Finanzierung wird nach wie vor national entschieden. Wer die Musik bestellt, der muss sie auch bezahlen, so heißt es im Deutschen. Aber dass ein Medikament in Frankreich das Leben um zwei Jahre verlängert und in Deutschland nur um sechs Monate oder umgekehrt, das kann nicht sein. Deswegen muss die Nutzenbewertung auf der wissenschaftlichen Basis in Europa gemeinsam gemacht werden. Die hochbezahlten Leute, die das 27 Mal machen, die sollen sich wirklich um die Innovationen kümmern und nicht um Doppelarbeit.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-127-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/197641.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20211213-20:14:12&amp;playerEndTime=20211213-20:15:29" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Sara Cerdas (S&amp;D).</span></span>   – Senhora Presidente, a pandemia revela, todos os dias, a importância de termos tecnologias em saúde inovadoras e acessíveis a todos capazes de apoiar a proteção e a promoção da saúde, bem como a prevenção da doença. </p>
<p class="contents">O reforço da cooperação na avaliação de tecnologias em saúde deve contribuir para que estas respondam às necessidades dos doentes, garantindo a proteção dos dados de saúde a todos os níveis, dos profissionais de saúde, reduzindo a carga burocrática e o trabalho administrativo através da automatização dos sistemas de saúde, através da padronização da recolha de dados e da interoperabilidade dos sistemas de informação e das instituições, permitindo uma maior transparência nos processos de avaliação técnica e de decisão política e promovendo um maior diálogo com as organizações envolvidas. </p>
<p class="contents">Precisamos, assim, de melhorar os instrumentos de prevenção, de diagnóstico e de tratamento que temos ao nosso dispor e é para este objetivo que esta regulamentação irá contribuir. </p>
<p class="contents">Parabéns ao relator e a todos os envolvidos pelo excelente trabalho alcançado. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-128-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/58766.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20211213-20:15:46&amp;playerEndTime=20211213-20:16:51" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Nicolae Ştefănuță (Renew).</span></span>   – Doamna președintă, doamna comisar, boala lungă e moarte sigură, spun românii. Dar uneori boala unor europeni este mult prea lungă. Asta pentru că avem reguli diferite pentru noi tehnologii medicale și noi medicamente. </p>
<p class="contents">Cum se face că în România accesul pacienților la cele mai noi medicamente poate fi mai lung și cu 240 de zile (adică cu 8 luni)? Mii de oameni mor în 8 luni și este nepermis ca ei să moară cu leacul pe masă, ascuns în sertarele vreunui birocrat. Mulți iau drumul străinătății, nevoiți să plătească din buzunarele proprii, sau chiar făcând împrumuturi extrem de scumpe. </p>
<p class="contents">Evaluarea tehnologiilor medicale coordonată la nivel european ne va permite să reducem considerabil timpul de așteptare pentru pacienții noștri și astfel să salvăm vieți europene. „Pentru orice rău există două leacuri, timpul și tăcerea”, a spus Alexandre Dumas. Să reducem timpul suferinței, să rupem tăcerea!</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-129-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/193292.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20211213-20:17:02&amp;playerEndTime=20211213-20:18:17" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Tilly Metz (Verts/ALE).</span></span>   – Madam President, after years of difficult negotiations, I am glad to finally see a deal on this file, as it will guarantee more equal access to quality medicines and medical devices throughout the Union. So congratulations to the rapporteur and to all the shadow rapporteurs. </p>
<p class="contents">Too often, expensive medicines, which do not really make a difference to what already exists on the market, still get approved. With HTA we will avoid duplication of clinical assessment – and hence of human and financial resources.</p>
<p class="contents">I am happy to see that we have managed to integrate enhanced transparency and public access to HTA documents into the text, safeguards in case Member States still carry out national clinical assessments, as well as the establishment of a stakeholder network to guarantee civil society involvement. </p>
<p class="contents">All in all, I am delighted to see that governments are now given every means to reimburse only medicines that truly work so that patients only access and pay for effective treatments.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-130-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/197841.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20211213-20:18:29&amp;playerEndTime=20211213-20:19:55" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Liudas Mažylis (PPE).</span></span>   – Gerbiama Pirmininke, gerbiama Komisijos nare, kolegos, kalbame apie Europos sveikatos sąjungą, o pažangios sveikatos technologijos diegiamos paskirai, nesant netgi stabilaus finansavimo. Per tą laiką COVID-19 iššūkiai įrodė, kaip svarbu veikti kartu. Bendro valstybių veikimo būtinybė tapo akivaizdi, svarstant kovos su vėžiu strategiją, farmacijos strategiją.</p>
<p class="contents">Džiaugiuosi, kad pagaliau susitarta ir dėl šio instrumento. Tai tam tikras žingsnis į priekį, didinant sveikatos sistemų konvergenciją, ir, tikėtina, mažinant biurokratizmą. Tai ‒ žingsnis link vienodesnių galimybių taikyti pažangias medicinos technologijas bet kurios valstybės pacientams.</p>
<p class="contents">Valstybėms, turinčioms mažesnius resursus, bendri klinikiniai tyrimai, bendri vertinimai būtų naudingi. Ilgainiui per tai susilygintų ir pacientų galimybės. Inovatyvūs gydymo būdai, ypač orientuoti į sunkiai pagydomas ligas, jų atnešama pridėtinė vertė turi būti įvertinami kaip įmanoma greičiau ir skaidriau. Apgailestaudamas, kad valstybėms narėms bendrų klinikinių vertinimų pranešimai nebus įpareigojantys, tikiu, kad efektyvus ir sklandus bendradarbiavimas, vertinant sveikatos technologijas, galėtų prisidėti prie visų Europos pacientų sveikatos gerinimo.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-131-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/197718.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20211213-20:20:09&amp;playerEndTime=20211213-20:21:28" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Nicolás González Casares (S&amp;D).</span></span>   – Señora presidenta, señor Wölken, enhorabuena a todos los ponentes por este trabajo, que ha sido de largo recorrido. Se ha tardado años en llevar a buen puerto algo que ya había comenzado mi compañera Soledad Cabezón: acercar —y hacer más transparente— la evaluación de las tecnologías sanitarias en un momento en que es mucho más necesario.</p>
<p class="contents">Con todas las disrupciones y los avances que estamos viviendo derivados de la pandemia, sabemos que vamos a invertir más en tecnologías sanitarias. Necesitamos no solo evaluarlas correctamente y saber que funcionan, sino también compartir y coordinar esos esfuerzos en toda la Unión Europea, y además hacerlo transparentemente para todos.</p>
<p class="contents">Vamos camino de la medicina personalizada, de nuevos fármacos adaptados, casi individualizados, a los pacientes que los necesitan; a nuevas fuentes de datos; a la inteligencia artificial. Tenemos que ser conscientes de que, compartiendo todos y haciendo más vinculantes las decisiones, avanzaremos hacia una mejor salud, más igualitaria para todos, europeos y europeas, así que también felicito a la Comisión por este paso.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-132-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124799.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20211213-20:21:38&amp;playerEndTime=20211213-20:22:54" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Alessandra Moretti (S&amp;D).</span></span>   – Signora Presidente, signora Commissaria, onorevoli colleghi, ringrazio la Commissaria e il collega Wölken per il lavoro svolto insieme agli altri relatori su un tema così delicato e importante. Credo che il risultato finale sia un buon compromesso nell'interesse di tutti i cittadini europei.</p>
<p class="contents">La valutazione delle tecnologie sanitarie è un passaggio estremamente delicato, perché talvolta si svolge con pazienti in attesa di nuove opportunità di cure. Allo stesso tempo serve un processo rigoroso, perché nessun apparecchio medico o terapia può essere approvato senza un vero valore aggiunto per i cittadini.</p>
<p class="contents">Bene la strada tracciata di una maggiore integrazione e coordinamento tra le diverse autorità nazionali, sapendo che questa è una delle tipiche situazioni in cui l'Europa può giocare un ruolo fondamentale nell'interesse dei cittadini e dei pazienti.</p>
<p class="contents">Credo che questa misura debba essere considerata come un punto di partenza, pronti a un'ulteriore integrazione a livello europeo, se la situazione su questo terreno dedicato lo richiedesse.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-133-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/doceo/data/img/photo_generic.gif" align="right" width="50" height="63" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20211213-20:23:08&amp;playerEndTime=20211213-20:26:13" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Stella Kyriakides,</span></span>   <span class="italic">Member of the Commission</span><span class="bold">.</span> – Madam President, honourable Members, as many of us have said, today is an important day for patients across the EU and I want to thank you once again for the very important part you have all played in getting us to this point. I very much appreciate the support for the regulation’s objectives and ambitions.</p>
<p class="contents">MEP Guteland, MEP Trillet-Lenoir, yes, we can only agree that the Regulation on Health Technology Assessment (HTA) will ensure the effective use of resources, as you have said, and strengthen the quality of HTA across the EU; and of course, as you have said, it is a fundamental right to have access for all patients.</p>
<p class="contents">MEP Colin-Oesterlé, the joint work will start by assessing cancer medicines and advanced therapies like gene therapy and of course, as many of us said, unmet medical needs are our focus and a priority.</p>
<p class="contents">MEP Liese, I just wanted to stand on one or two points because the significance for cancer patients has already been stressed, but also avoiding the duplication of work, and I just wanted to share with you the role of working together and what we have today, where we are today, and now with the therapeutic strategy we will be reaching this week the target of five authorised therapeutics for COVID-19 at the EU level, and we will work with all for joint procurement to ensure timely access.</p>
<p class="contents">MEP Ştefănuță spoke of the unequal access to medicines in the EU, as did MEP Metz and others, and I just wanted to say that really it is not acceptable. We will be addressing this through the pharmaceutical legislation. We need to save resources, we need to have transparency. I’ll end with what MEP Moretti just said: that HTA is challenging. But the fact that it is challenging I think makes it even more important that we have managed to reach this point together.</p>
<p class="contents">As of next month, we will begin operational steps with setting up key governance bodies such as the coordination group and the stakeholder network. We will also start preparing the necessary implementing and delegated acts. We will assist the coordination group with the drafting of a guidance document and really, we need to bring all these rules now to life.</p>
<p class="contents">I very much look forward to continuing to work with you. I will keep you informed on all the progress, and thank you once again for your continued support.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-134-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/185619.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20211213-20:26:21&amp;playerEndTime=20211213-20:28:38" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Tiemo Wölken, </span></span>  <span class="italic">Berichterstatter</span><span class="bold">.</span> – Frau Präsidentin! Noch einmal vielen Dank heute. Und Gott sei Dank – ich hatte mich gerade ein bisschen unwohl gefühlt – waren so viele Ärztinnen und Ärzte hier im Raum. Alles gut – vielen Dank an die Kolleginnen und Kollegen. </p>
<p class="contents">Ich möchte mich noch einmal für die Zusammenarbeit bedanken. Ich glaube, dass wir hier etwas Großes geschafft haben. Und ich möchte noch mal unseren Teams Danke sagen, unseren Sekretariaten Danke sagen für diese Zusammenarbeit. Ich habe es gesagt: über vier Jahre Verhandlungen – das ist nicht einfach. </p>
<p class="contents">Ich will es kurz machen. Ich hoffe, sehr geehrte Frau Kommissarin, dass wir die gefundenen Regeln jetzt auch schnell umsetzen und vor allen Dingen auch konzentriert umsetzen. Und dafür braucht es meiner Meinung nach ein HTA—Sekretariat, das wir beschlossen haben, das zentral geordnet ist, das entweder in einer neuen Agentur oder aber in einer bestehenden Agentur angesiedelt wird. </p>
<p class="contents">Und, Frau Kommissarin, ich hätte eine Bitte: das Sekretariat mit ausreichend Ressourcen auszustatten und dafür zu sorgen, dass keine Unklarheiten über Prozesse entstehen können. Das zukünftige Sekretariat wird das Rückgrat für diese Verordnung sein und wird sicherstellen, dass diese Gesundheitsbewertung überall in der Europäischen Union tatsächlich auch funktionieren kann. Deswegen ist es wirklich wichtig, dass das Sekretariat gut arbeiten kann, und ich hoffe, dass das möglich gemacht wird. Denn der Punkt ist, dass wir Doppelarbeit vermeiden wollen, dass wir neue Gesundheitstechnologien schnell und günstig an die und für die Europäerinnen und Europäer zur Verfügung stellen wollen. Und dafür brauchen wir Sie in der Europäischen Kommission. </p>
<p class="contents">Ich möchte mich ganz am Ende auch noch einmal bei der portugiesischen Ratspräsidentschaft bedanken, die wirklich auch dazu mit beigetragen hat, dass wir hier zu einem Erfolg kommen konnten. Am Ende sind sowohl Parlament als auch Rat und auch die Kommission aufeinander zugegangen. Und deswegen glaube ich, dass wir jetzt am Ende des Tages ein Gesetz haben, das den Bürgerinnen und Bürgern wirklich hilft. Und deswegen vielen Dank und danke noch mal für die etwas längere Zeit.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-135-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/2054.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20211213-20:28:36&amp;playerEndTime=20211213-20:29:51" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Puhemies. – </span></span>  Keskustelu on päättynyt.</p>
<p class="contents">Tämän suosituksen toiseen käsittelyyn osalta käsiteltäväksi ei ole jätetty ehdotuksia neuvoston kannan hylkäämiseksi eikä yhtään tarkistusta työjärjestyksen 67 ja 68 artiklan nojalla. </p>
<p class="contents">Neuvoston kanta katsotaan näin ollen hyväksytyksi ja täten myös ehdotettu säädös on hyväksytty.</p>
<p class="contents"><span class="bold"><span class="italic">Kirjalliset lausumat (171 artikla)</span></span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-135-5000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124765.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Joëlle Mélin (ID), </span></span>  <span class="italic">par écrit</span><span class="bold">.</span> – Comme toujours, ce qui devrait être une bonne idée devient, une fois passée à la « moulinette » des Trilogues, un mauvais compromis mal équilibré, pétri d’intérêts contraires qui oublie un élément central, mais néanmoins important: l’intérêt du citoyen! </p>
<p class="contents">Si nous comprenons l’utilité d’une collaboration intra-européenne sur l’évaluation de certaines technologies de santé, nous n’acceptons pas, en revanche, que les États membres se voient dicter leurs systèmes de santé par l’UE. Que les évaluations soient obligatoires ou non, qu’elles soient conjointes ou non, il n’en reste pas moins qu’elles sont intrinsèquement liées aux décisions de prise en charge des produits et à la négociation des prix dans chaque États membres. </p>
<p class="contents">Avec ce processus, seules les technologies de santé qui trouveront grâce aux yeux de l’UE pourront encore être utilisées et prescrites dans l’UE, là où les autres finiront immanquablement par disparaitre, faute de remboursement. Cela mènera, au final, à la disparition pure et simple de nombreuses spécialités médicamenteuses, pourtant très utiles. Nous rejetons ces contraintes administratives et cette judiciarisation des processus qui ne servent qu’à bloquer la liberté de soins.</p></td><td width="16"> </td></tr></table></td></tr></table><table width="100%" border="0" cellspacing="0" cellpadding="5"><tr class="footerdocwin"><td>Last updated: 23 February 2022</td><td align="right"><a target="_blank" href="/legal-notice/en">Legal notice</a> - <a target="_blank" href="/privacy-policy/en">Privacy policy</a></td></tr></table></td></tr></table></body></html>
